Denali Therapeutics Inc.

51.00-1.90-3.59%Vol 568.85K1Y Perf 46.57%
Sep 24th, 2021 16:00 DELAYED
BID50.91 ASK51.00
Open51.93 Previous Close52.90
Pre-Market- After-Market-
 - -  - -%
Target Price
84.40 
Analyst Rating
Strong Buy 1.54
Potential %
65.49 
Finscreener Ranking
★★★★     53.71
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     53.70
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     78.04
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
27.95 
Earnings Rating
Sell
Market Cap6.20B 
Earnings Date
4th Nov 2021
Alpha0.02 Standard Deviation0.22
Beta1.87 

Today's Price Range

50.7052.86

52W Range

34.3493.94

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-3.46%
1 Month
-2.32%
3 Months
-31.71%
6 Months
-8.27%
1 Year
46.57%
3 Years
140.11%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
DNLI51.00-1.9000-3.59
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.37-0.50-35.14
Q01 2021-0.37-0.58-56.76
Q04 2020-0.551.91447.27
Q03 20203.57-0.54-115.13
Q02 2020-0.61-0.568.20
Q01 2020-0.57-0.553.51
Q04 2019-0.53-0.56-5.66
Q03 2019-0.53-0.489.43
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.49-4.26Negative
12/2021 QR-0.360.00-
12/2021 FY-1.96-7.10Negative
12/2022 FY-2.40-0.84Negative
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.51
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume568.85K
Shares Outstanding121.64M
Shares Float78.41M
Trades Count9.05K
Dollar Volume39.54M
Avg. Volume583.50K
Avg. Weekly Volume656.91K
Avg. Monthly Volume576.06K
Avg. Quarterly Volume589.45K

Denali Therapeutics Inc. (NASDAQ: DNLI) stock closed at 51 per share at the end of the most recent trading day (a -3.59% change compared to the prior day closing price) with a volume of 569.56K shares and market capitalization of 6.20B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 291 people. Denali Therapeutics Inc. CEO is Ryan J. Watts.

The one-year performance of Denali Therapeutics Inc. stock is 46.57%, while year-to-date (YTD) performance is -39.11%. DNLI stock has a five-year performance of %. Its 52-week range is between 34.34 and 93.94, which gives DNLI stock a 52-week price range ratio of 27.95%

Denali Therapeutics Inc. currently has a PE ratio of 80.00, a price-to-book (PB) ratio of 5.99, a price-to-sale (PS) ratio of 16.99, a price to cashflow ratio of 15.60, a PEG ratio of 2.32, a ROA of 5.19%, a ROC of 6.53% and a ROE of 7.10%. The company’s profit margin is 15.66%, its EBITDA margin is 16.70%, and its revenue ttm is $357.07 Million , which makes it $2.94 revenue per share.

Of the last four earnings reports from Denali Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.51 for the next earnings report. Denali Therapeutics Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Denali Therapeutics Inc. is Strong Buy (1.54), with a target price of $84.4, which is +65.49% compared to the current price. The earnings rating for Denali Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Denali Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Denali Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.64, ATR14 : 2.55, CCI20 : -110.26, Chaikin Money Flow : -0.01, MACD : -0.66, Money Flow Index : 31.10, ROC : -4.15, RSI : 43.94, STOCH (14,3) : 27.42, STOCH RSI : 0.51, UO : 48.45, Williams %R : -72.58), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Denali Therapeutics Inc. in the last 12-months were: Alexander O. Schuth (Option Excercise at a value of $6 151), Alexander O. Schuth (Sold 157 059 shares of value $10 586 301 ), Carole Ho (Option Excercise at a value of $279 344), Carole Ho (Sold 76 135 shares of value $3 538 910 ), David P. Schenkein (Option Excercise at a value of $0), David P. Schenkein (Sold 80 000 shares of value $5 905 312 ), Douglas Bratton (Sold 64 624 shares of value $5 179 284 ), Douglas G. Cole (Option Excercise at a value of $0), Douglas K. Bratton (Sold 2 281 422 shares of value $149 271 156 ), Jay T. Flatley (Option Excercise at a value of $0), Jennifer Cook (Option Excercise at a value of $0), Marc Tessier-Lavigne (Option Excercise at a value of $1 765 275), Marc Tessier-Lavigne (Sold 294 378 shares of value $19 098 437 ), Peter S. Klein (Option Excercise at a value of $0), Robert T. Nelsen (Option Excercise at a value of $0), Ryan J. Watts (Option Excercise at a value of $0), Ryan J. Watts (Sold 233 629 shares of value $15 851 327 ), Steve E. Krognes (Option Excercise at a value of $0), Steve E. Krognes (Sold 156 768 shares of value $10 356 705 ), Vicki L. Sato (Sold 11 262 shares of value $675 934 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (66.67 %)
8 (66.67 %)
8 (72.73 %)
Moderate Buy
1 (8.33 %)
1 (8.33 %)
1 (9.09 %)
Hold
3 (25.00 %)
3 (25.00 %)
2 (18.18 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.54
Strong Buy
1.54
Strong Buy
1.41

Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

CEO: Ryan J. Watts

Telephone: +1 650 866-8548

Address: 161 Oyster Point Boulevard, South San Francisco 94080, CA, US

Number of employees: 291

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

57%43%

News

Stocktwits